soul trial oral semaglutide cardiovascular outcomes 2024 results Semaglutide's Impact on Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: soul trial oral semaglutide cardiovascular

Concurrently, GLP-1 stimulates the translocation of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) into the nucleus via the PKA/ERK signaling pathway, where Nrf2 induces transcription of genes for SOD, GPx, catalase, thioredoxin, and other antioxidant enzymes, further enhancing the cellular antioxidant defense system

Compared to native glucagon and GLP-1, retatrutide shows lower potency at GLP-1 and glucagon receptors but higher potency at the GIP receptor

This issue has even prompted some countries, like Australia, to ban compounded tirzepatide

Retatrutide activates three GIP, GLP-1, and glucagon

True non-response is defined as less than 5% weight loss after 12 continuous weeks at therapeutic doses, with a plateau despite dose escalation